<DOC>
	<DOC>NCT00693238</DOC>
	<brief_summary>The purpose of this trial is to give a shorter course (5 ½ weeks) of radiation that has as little side effects on normal bladder and rectal tissues as the usual longer course (8 weeks) of radiation, without decreasing the chance of killing prostate cancer cells.</brief_summary>
	<brief_title>Proton Therapy for Low and Intermediate Risk Prostate Cancer</brief_title>
	<detailed_description>Low Risk - Total of 70 Gy/CGE over 28 treatments Intermediate Risk - Total of 72.5 Gy/CGE over 29 treatments</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Inclusion Criteria Prostate cancer. Gleason score 27. PSA ≤ 20 ng/ml. Previous prostate cancer surgery or pelvic radiation. Prior or current chemotherapy for prostate cancer. Active inflammatory bowel disease (Crohn's disease, diverticulitis or ulcerative colitis) affecting the rectum. History of proximal urethral stricture requiring dilatation. History of hip replacement. Diabetes requiring medication. Prior intrapelvic surgery. Current and continuing anticoagulation with Warfarin sodium (Coumadin), Clopidogrel bisulfate (Plavix), enoxaparin sodium (Lovenox), or aspirin/er dipyridamole (Aggrenox). On Flomax (Tamsulosin), Hytrin (Terazosin) or Cardura (Doxazosin), Uroxatral (alfuzosin HCl). Taking Saw Palmetto or methotrexate and unable or unwilling to discontinue its use during radiation.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Prostate Cancer</keyword>
	<keyword>Proton Radiation</keyword>
</DOC>